



Paris, 26th july ,2017

Dear John F. Milligan, Gilead CEO

As treatment activists gathered at the International AIDS conference 2017 in Paris,
We would like to bring to your attention the following community demands:

Your prices for hepatitis C drugs are extremely high and cannot be afforded by most countries: 32.000 \$ in France, 12.000\$ in Malaysia, 4.500\$ in Brazil. Your voluntary licenses, supposed to increase access in developing world, exclude several high burden middle-income countries even where Gilead has no patent rights, thus imposing severe restrictions on production and circulation of active pharmaceutical ingredients that are needed by local manufacturers in developing countries.

We urge you to lower your prices for Hepatitis C drugs to affordable levels, increase the territory of your voluntary licenses to include ALL low and middle-income countries and remove all restrictions on production and circulation of active pharmaceutical ingredients.

In some countries, you have managed to obtain additional protection certificates beyond the initial duration of the Truvada patent. Today, generic producers are ready to enter markets with more affordable versions of the drug that is urgently needed to scale up access to PrEP. Such patent protections will delay market entry of these generics.

We urge you to respect the initial duration of the patent expiring now, and refrain from any attempt to block the marketing of corresponding generics.

Yours sincerely,

Aurelien Beaucamp, AIDES, President

Vincent Pelletier, Coalition PLUS, General Director

Othoman Mellouk, ITPC, Intellectual Property and Access to Medicines Lead